Taysha Gene Therapies Inc. (TSHA): Price and Financial Metrics
GET POWR RATINGS... FREE!
TSHA Stock Price Chart Interactive Chart >
TSHA Price/Volume Stats
| Current price | $1.64 | 52-week high | $8.93 |
| Prev. close | $1.54 | 52-week low | $1.35 |
| Day low | $1.52 | Volume | 780,696 |
| Day high | $1.71 | Avg. volume | 469,998 |
| 50-day MA | $2.10 | Dividend yield | N/A |
| 200-day MA | $2.95 | Market Cap | 102.40M |
Taysha Gene Therapies Inc. (TSHA) Company Bio
Taysha Gene Therapies, Inc. engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II on September 20, 2019 and is headquartered in Dallas, TX.
Latest TSHA News From Around the Web
Below are the latest news stories about TAYSHA GENE THERAPIES INC that investors may wish to consider to help them evaluate TSHA as an investment opportunity.
Biotech signals potential pullback from 200-job Durham plantState officials have terminated an incentive agreement for a Texas-based biotech that had planned to invest $75 million in a manufacturing facility in Durham. The state's Economic Investment Committee, part of the North Carolina Department of Commerce, voted unanimously Tuesday to terminate a package awarded to Taysha Gene Therapies (Nasdaq: TSHA) in late 2020. The vote was in response to a letter the department received from the company requesting withdrawal from the state's Job Development Investment Grant program. |
How did Taysha Gene Therapies Inc. (TSHA) fare last session?In Wednesday’s session, Taysha Gene Therapies Inc. (NASDAQ:TSHA) marked $2.12 per share, down from $2.20 in the previous session. While Taysha Gene Therapies Inc. has underperformed by -3.64%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TSHA fell by -82.12%, with highs and lows ranging from […] |
These strategies will help Taysha Gene Therapies Inc. (TSHA) succeedAs of Tuesday, Taysha Gene Therapies Inc.’s (NASDAQ:TSHA) stock closed at $1.91, down from $2.08 the previous day. While Taysha Gene Therapies Inc. has underperformed by -8.17%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TSHA fell by -84.93%, with highs and lows ranging from $13.31 […] |
Have you been able to find a good deal on Taysha Gene Therapies Inc.’s shares?The share price of Taysha Gene Therapies Inc. (NASDAQ:TSHA) fell to $1.94 per share on Monday from $2.14. While Taysha Gene Therapies Inc. has underperformed by -9.35%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TSHA fell by -87.08%, with highs and lows ranging from $15.24 […] |
Taysha Gene Therapies names new CEO (NASDAQ:TSHA)Taysha Gene Therapies'' (TSHA) Chair of the Board of Directors, Sean P |
TSHA Price Returns
| 1-mo | -27.43% |
| 3-mo | -6.29% |
| 6-mo | -61.68% |
| 1-year | -79.37% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -27.43% |
| 2022 | -80.60% |
| 2021 | -56.10% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...